Merck
2Q Revenues: $5.8 billion (+6%)
2Q Earnings: $1.5 billion (+108%)*
YTD Reveneus: $11.2 billion (+3%)
YTD Earnings: $3 billion (+44%)
Comments: Zocor sales were $990 million, down 14% due to loss of marketing exclusivity. Singulair sales reached $950 million, up 30%. Rotateq sales were $31 million for the quarter. The Merck/Schering-Plough partnership reported global sales of Zetia and Vytorin reached $973 million as compared to $507 million in 2Q2005. R&D expenses were $1.2 billion for the quarter, up 24%, including $296 million recorded in the quarter for acquired research resulting from the GlycoFi acquisition. The company received product approvals for Gardasil and Zostavax in the quarter.
*Results reflect restructuring costs and a credit of $7 million related to separations as well as gains on the sales of facilities associated with the company's restructuring program.
Magazine
